CA2970546A1 - Antimicrobial polymyxins for treatment of bacterial infections - Google Patents

Antimicrobial polymyxins for treatment of bacterial infections Download PDF

Info

Publication number
CA2970546A1
CA2970546A1 CA2970546A CA2970546A CA2970546A1 CA 2970546 A1 CA2970546 A1 CA 2970546A1 CA 2970546 A CA2970546 A CA 2970546A CA 2970546 A CA2970546 A CA 2970546A CA 2970546 A1 CA2970546 A1 CA 2970546A1
Authority
CA
Canada
Prior art keywords
compound
cr4r5
aryl
cr6r7
6alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2970546A
Other languages
English (en)
French (fr)
Inventor
Mikhail Fedorovich Gordeev
Jinqian Liu
Xinghai Wang
Zhengyu Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MICURX PHARMACEUTICALS Inc
Original Assignee
MICURX PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MICURX PHARMACEUTICALS Inc filed Critical MICURX PHARMACEUTICALS Inc
Publication of CA2970546A1 publication Critical patent/CA2970546A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
CA2970546A 2014-12-16 2015-12-16 Antimicrobial polymyxins for treatment of bacterial infections Pending CA2970546A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462092780P 2014-12-16 2014-12-16
US62/092,780 2014-12-16
PCT/US2015/066210 WO2016100578A2 (en) 2014-12-16 2015-12-16 Antimicrobial polymyxins for treatment of bacterial infections

Publications (1)

Publication Number Publication Date
CA2970546A1 true CA2970546A1 (en) 2016-06-23

Family

ID=55456866

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2970546A Pending CA2970546A1 (en) 2014-12-16 2015-12-16 Antimicrobial polymyxins for treatment of bacterial infections

Country Status (8)

Country Link
US (1) US9771394B2 (https=)
EP (1) EP3233889B1 (https=)
JP (1) JP6896628B2 (https=)
KR (1) KR102585108B1 (https=)
CN (1) CN107257803B (https=)
CA (1) CA2970546A1 (https=)
ES (1) ES2924058T3 (https=)
WO (1) WO2016100578A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189866A1 (en) * 2016-04-27 2017-11-02 Spero Opco Polymyxin analogs useful as antibiotic potentiators
EP3388445A1 (en) * 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Peptide macrocycles and use thereof in the treatment of bacterial infections
CN111527100A (zh) 2017-11-02 2020-08-11 昆士兰大学 肽类抗生素
WO2019237186A1 (en) * 2018-06-12 2019-12-19 University Of Manitoba Preparation of dilipid polymyxins and use thereof as antimicrobial adjuvants
CN111690040A (zh) * 2019-03-12 2020-09-22 上海来益生物药物研究开发中心有限责任公司 多粘菌素衍生物、其制备方法和应用
GB201904534D0 (en) * 2019-04-01 2019-05-15 Centauri Therapeutics Ltd Novel compounds an therapeutic uses thereof
CN112300247B (zh) * 2019-07-24 2022-12-27 广东东阳光药业有限公司 一种Teixobactin类似物及其用途
JP7045520B2 (ja) * 2020-01-02 2022-03-31 上海上薬第一生化薬業有限公司 ポリミキシンｂ成分又はその塩、その製造方法及び使用
WO2021150792A1 (en) 2020-01-21 2021-07-29 Micurx Pharmaceuticals, Inc. Novel compounds and composition for targeted therapy of kidney-associated cancers
JP7755347B2 (ja) * 2021-07-21 2025-10-16 シャンハイ ミクウルク ファーマシューティカル シーオー．エルティーディー 腎癌の標的治療のための新規化合物及び組成物
US20250109171A1 (en) * 2021-07-21 2025-04-03 Shanghai MICURX Pharmaceuticals Co., Ltd. Compounds and compositions for targeted therapy of renal diseases

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3450687A (en) 1966-02-24 1969-06-17 Pfizer & Co C Lower alkanoyl esters of polymyxin antibiotics
DE1906699A1 (de) 1968-02-12 1970-02-05 Pfizer Neue Polymyxinderivate und Verfahren zu deren Herstellung
US4091092A (en) 1976-09-20 1978-05-23 E. R. Squibb & Sons, Inc. Polymyxin F and process of producing polymyxin F
JPS5831918B2 (ja) 1976-10-27 1983-07-09 塩野義製薬株式会社 新規抗生物質ポリミキシンｓ↓１
US6380356B1 (en) 1999-12-07 2002-04-30 Advanced Medicine, Inc. Multivalent polymyxin antibiotics
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
WO2006045156A1 (en) 2004-10-29 2006-05-04 Monash University Therapy for multi-drug resistant microorganisms
KR100750658B1 (ko) 2005-12-09 2007-08-20 한국생명공학연구원 폴리믹신 생합성 효소 및 이를 코딩하는 유전자 군
US7807637B2 (en) 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
BRPI0715095B8 (pt) 2006-08-11 2021-05-25 Northern Antibiotics Oy derivado de polimixina da fórmula geral (i); produto de combinação; composição farmacêutica; método para se sensibilizar bactérias gram-negativas a um agente antibacteriano; método para o desenvolvimento de antibióticos; método para a redução da toxicidade de polimixinas, octapeptinas naturais e seus derivados durante a aplicação das mesmas no tratamento de infecções em um indivíduo; método para melhorar as propriedades farmacocinéticas, de polimixinas, octapeptinas naturais e seus derivados; método para a sensibilização de bactérias gram-negativas clinicamente importantes a um complemento de mecanismo de defesa presente no soro; uso de um derivado; e processo para a preparação de um derivado de polimixina da fórmula (i).
US9096649B2 (en) 2008-02-08 2015-08-04 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
FI20085469A0 (fi) * 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
CA2747995A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US8389679B2 (en) 2009-02-05 2013-03-05 The Regents Of The University Of California Targeted antimicrobial moieties
WO2010130007A1 (en) * 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
JP5626737B2 (ja) 2009-09-01 2014-11-19 ファブ ファーマ エスエーエス 新規抗菌性ヒドロキシフェニル化合物
JP5353680B2 (ja) 2009-12-18 2013-11-27 船井電機株式会社 光ディスク装置
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
WO2012168820A1 (en) 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
CA2855916A1 (en) 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
CN103130876B (zh) 2011-11-30 2014-07-23 广东双柏药业有限公司 一种高纯度多粘菌素b的制备方法
WO2013112548A1 (en) 2012-01-23 2013-08-01 University Of South Florida Gamma-aapeptides with potent and broad-spectrum antimicrobial activity
WO2014028087A1 (en) 2012-08-17 2014-02-20 University Of Houston Liposomal formulations of polymyxin and uses thereof
JP6334546B2 (ja) 2012-10-18 2018-05-30 ダウ グローバル テクノロジーズ エルエルシー リン含有カルボン酸アルミニウム塩難燃剤
CN103044529B (zh) * 2012-12-06 2018-01-30 山东鲁抗医药股份有限公司 一种在硫酸多粘菌素b中提取b1单组份的方法
KR20150107793A (ko) 2013-01-11 2015-09-23 셀리아 파마슈티칼즈 에이피에스 폴리믹신, 조성물, 제조 방법 및 사용 방법
CN103923190B (zh) 2013-01-14 2018-04-03 上海医药工业研究院 从多黏菌素b的混合组分中分离纯化多黏菌素b1的方法
KR102354902B1 (ko) * 2013-05-22 2022-01-24 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도
WO2015031602A1 (en) 2013-08-29 2015-03-05 Rhk Technology, Inc. Optical alignment interface
MX359104B (es) 2014-03-11 2018-09-14 New Pharma Licence Holdings Ltd Derivados de polimixina y su uso en terapia de combinacion junto con diferentes antibioticos.
JP2017512818A (ja) 2014-04-01 2017-05-25 モナシュ、ユニバーシティＭｏｎａｓｈ Ｕｎｉｖｅｒｓｉｔｙ 抗菌性化合物としてのポリミキシン誘導体

Also Published As

Publication number Publication date
JP2018502845A (ja) 2018-02-01
KR20170086671A (ko) 2017-07-26
CN107257803B (zh) 2021-02-05
JP6896628B2 (ja) 2021-06-30
WO2016100578A2 (en) 2016-06-23
KR102585108B1 (ko) 2023-10-05
US20160185823A1 (en) 2016-06-30
EP3233889A2 (en) 2017-10-25
EP3233889B1 (en) 2022-07-06
ES2924058T3 (es) 2022-10-04
WO2016100578A3 (en) 2016-08-11
CN107257803A (zh) 2017-10-17
US9771394B2 (en) 2017-09-26

Similar Documents

Publication Publication Date Title
CA2970546A1 (en) Antimicrobial polymyxins for treatment of bacterial infections
CN109422752B (zh) 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物
EP3565815B1 (en) Compounds as bcl-2-selective apoptosis-inducing agents
EP3445357B1 (en) Bifunctional molecules for degradation of egfr and methods of use
CN110546151A (zh) 凋亡诱导剂
WO2016145258A1 (en) Anti-alphavbeta1 integrin inhibitors and methods of use
KR102842676B1 (ko) Khk 억제 효과를 갖는 화합물
BR112020019399A2 (pt) Compostos macrocíclicos como inibidores de trk quinases
EP4079748A1 (en) Modulators of sortilin activity
EP3929185A1 (en) Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof
CA3217317A1 (en) Compounds
WO2019241131A1 (en) Muscarinic acetylcholine m1 receptor antagonists
JP2023525748A (ja) Ｂｃｌ－２阻害剤としての化合物
KR102804113B1 (ko) 알킬 다이하이드로퀴놀린 설폰아마이드 화합물
JP2023549187A (ja) 貧血およびがんの処置のためのｖｈｌ阻害剤としての１－（２－（４－シクロプロピル－１ｈ－１，２，３－トリアゾール－１－イル）アセチル）－４－ヒドロキシ－ｎ－（ベンジル）ピロリジンｅ－２－カルボキサミド誘導体
CA3206847A1 (en) Modulators of fpr1 and methods of using the same
JP7723030B2 (ja) チアゾロ［５，４－ｂ］ピリジンＭＡＬＴ－１阻害剤
JP7692002B2 (ja) 新規な２－アリールチアゾール誘導体またはその塩、その製造方法、及びそれを含む医薬組成物
EP3544965A1 (en) Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2, 3-dioxygenase
WO2018211324A1 (en) Prodrugs for the treatment of disease
JP2020500907A (ja) 細胞外クエン酸の取込みの阻害剤としてのスルホンアミド
AU2020410900A1 (en) Compound used as RET kinase inhibitor and application thereof
CN109422753A (zh) 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物
RU2782469C2 (ru) Апоптоз-индуцирующие агенты

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201215

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240923

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240923

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240923

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241010

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250102

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250514

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250514

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250714

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250714

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260216

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260216